OBJECTIVES: To determine the risk of serious infection in patients with rheumatoid arthritis (RA) receiving etanercept (ETN) or disease-modifying anti-rheumatic drugs (DMARDs) and to identify factors that predict a higher risk. METHODS: Five-year data from the British Society of Rheumatology Biologics Register (BSRBR), a prospective observational study of patients with active RA treated with ETN, were used. These data were compared with a cohort of patients receiving DMARDs with active RA. RESULTS: Total follow-up was 19,964 patient-years (py; ETN, 14,381 py; DMARDs, 5583 py). Over the study period, 651 first-recorded serious infections were reported (ETN, 469 [39.9 per 1000 py]; DMARDs, 182 [35.0 per 1000 py]). Overall the risk of serious infection was similar for the 2 treatments; however, in the first 6 months of treatment the hazard ratio (HR) was higher in the ETN than the DMARD group (1.979; p=0.015). A linear association was observed between the serious infection rate and disease-activity score in 28 joints (DAS28) in patients from each treatment group and overall (DAS28 <4, 27.1 per 1000 py; DAS28 ≥8, 64.4 per 1000 py; 7.5% increase in serious infection for each unit increase of DAS28 score at baseline). In a time-dependent analysis, a DAS28 change of 1 unit during follow-up predicted a 27% increase in serious infection rates. CONCLUSIONS: No significant increase in the risk of serious infection was observed with ETN versus DMARDs over the 5-year study; a linear relationship existed between the serious infection rate and disease activity, as measured by DAS28.
OBJECTIVES: To determine the risk of serious infection in patients with rheumatoid arthritis (RA) receiving etanercept (ETN) or disease-modifying anti-rheumatic drugs (DMARDs) and to identify factors that predict a higher risk. METHODS: Five-year data from the British Society of Rheumatology Biologics Register (BSRBR), a prospective observational study of patients with active RA treated with ETN, were used. These data were compared with a cohort of patients receiving DMARDs with active RA. RESULTS: Total follow-up was 19,964 patient-years (py; ETN, 14,381 py; DMARDs, 5583 py). Over the study period, 651 first-recorded serious infections were reported (ETN, 469 [39.9 per 1000 py]; DMARDs, 182 [35.0 per 1000 py]). Overall the risk of serious infection was similar for the 2 treatments; however, in the first 6 months of treatment the hazard ratio (HR) was higher in the ETN than the DMARD group (1.979; p=0.015). A linear association was observed between the serious infection rate and disease-activity score in 28 joints (DAS28) in patients from each treatment group and overall (DAS28 <4, 27.1 per 1000 py; DAS28 ≥8, 64.4 per 1000 py; 7.5% increase in serious infection for each unit increase of DAS28 score at baseline). In a time-dependent analysis, a DAS28 change of 1 unit during follow-up predicted a 27% increase in serious infection rates. CONCLUSIONS: No significant increase in the risk of serious infection was observed with ETN versus DMARDs over the 5-year study; a linear relationship existed between the serious infection rate and disease activity, as measured by DAS28.
Authors: Gareth J Treharne; Grace Johnstone; Benjamin D Fletcher; Roisin S M Lamar; Douglas White; Simon Stebbings; Andrew Harrison Journal: Musculoskeletal Care Date: 2021-08-13
Authors: Mark T Osterman; William J Sandborn; Jean-Frederic Colombel; Laurent Peyrin-Biroulet; Anne M Robinson; Qian Zhou; James D Lewis Journal: Am J Gastroenterol Date: 2016-09-27 Impact factor: 10.864
Authors: P S Rommer; T Dörner; K Freivogel; J Haas; B C Kieseier; T Kümpfel; F Paul; F Proft; H Schulze-Koops; E Schmidt; H Wiendl; U Ziemann; U K Zettl Journal: J Neuroimmune Pharmacol Date: 2015-11-20 Impact factor: 4.147
Authors: Leslie R Harrold; Heather J Litman; Katherine C Saunders; Kimberly J Dandreo; Bernice Gershenson; Jeffrey D Greenberg; Robert Low; Jeffrey Stark; Robert Suruki; Srihari Jaganathan; Joel M Kremer; Mohamed Yassine Journal: Arthritis Res Ther Date: 2018-01-02 Impact factor: 5.156
Authors: Paul Emery; Gerd R Burmester; Vivian P Bykerk; Bernard G Combe; Daniel E Furst; Michael A Maldonado; Tom Wj Huizinga Journal: RMD Open Date: 2019-02-08
Authors: Jeffrey R Curtis; Kevin Winthrop; Cathy O'Brien; Matladi N Ndlovu; Marc de Longueville; Boulos Haraoui Journal: Arthritis Res Ther Date: 2017-12-15 Impact factor: 5.156